---
company: INNOVATIVE INDUSTRIAL PROPERTIES INC
ticker: IIPR
form: 8-K
filed: 2026-11-02
accepted: 2026-11-02T21:50:38+00:00
accession: 0001677576-26-000005
source: https://www.sec.gov/Archives/edgar/data/1677576/000167757626000005/
---

# Innovative Industrial Properties (IIPR) Q3 2026 earnings

## Header

- Company: Innovative Industrial Properties Inc
- Reported: 2026-11-02 16:50 AMC ET
- Source: 8-K only — accession 0001677576-26-000005, Item 2.02 + Exhibit 99.1
- Verdict: AFFO per share increased 7% sequentially to $1.96, supported by higher interest and dividend income from IQHQ and a $245 million mezzanine loan commitment to Alewife Park.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $64.9M | +0.4% | +2.3% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.99 | +2.1% | -27.0% | Ex. 99.1, income statement |
| EPS (adjusted) | $1.96 | +14.6% | +7.1% | Ex. 99.1, income statement |
| Adj. EBITDA | $67.5M | +39.6% | +8.7% | Ex. 99.1, income statement |
| Adj. EBITDA margin | 104.1% | +39.6 pp | +8.7 pp | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $35.5M (+0.1% YoY)
- One-offs in the quarter: Impairment loss on real estate $567k; Stock-based compensation $3.3M; Litigation-related expense $784k
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: Adds back stock-based compensation, impairment loss on real estate, income on seller-financed notes, deferred lease payments, and transaction costs to arrive at Adjusted EBITDA.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---|---:|
| Total liquidity | $142.4M | $299.7M | — | -52.5% |
| Net Debt to Adjusted EBITDA | 2.1x | 1.7x | — | +0.4 pp |
| Total gross assets | $3.0B | $3.0B | — | — |
| Net debt to total gross assets | 18.7% | 14.2% | — | +4.5 pp |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: Total revenues increased 0.4% YoY to $64.9M, driven by higher rental revenue from properties repossessed during the quarter, partially offset by lower rental revenue from property sales and lease terminations.
- EPS story: EPS growth was driven by higher interest and dividend income from IQHQ and interest income on the seller-financed note, alongside a decrease in weighted average shares outstanding.
- One-off check: Impairment loss on real estate $567k; Stock-based compensation $3.3M; Litigation-related expense $784k.

## The good

- AFFO per share increased 7% sequentially to $1.96
- Interest and other income increased to $14.3M driven by $10.4M of interest and dividend income from IQHQ
- Executed a $245 million mezzanine loan commitment to Alewife Park

## The bad

- Net income attributable to common stockholders decreased 29.5% sequentially to $28.7M
- Total liquidity decreased 52.5% sequentially to $142.4M

## The ugly

- none

## Open questions

- The filing does not disclose the specific tax rate applied to arrive at GAAP net income.
- The filing does not disclose the specific tax rate applied to arrive at GAAP net income attributable to common stockholders.

## Full release

### Innovative Industrial Properties (IIPR) earnings release, November 2, 2026

Innovative Industrial Properties Inc (IIPR) · Form 8-K, Item 2.02 · Filed 2026-11-02 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1677576/000167757626000005/)

Innovative Industrial Properties Reports Third Quarter 2026 Results

$275 Million of Accretive Investment Activity During the Quarter

SAN DIEGO, CA – November 2, 2026 – Innovative Industrial Properties, Inc. (NYSE: IIPR) ("IIP" or the "Company") announced today results for the third quarter ended September 30, 2026.

Executive Chairman Remarks

“We are pleased to report strong earnings with our AFFO per share up 7% compared to the second quarter, and are encouraged by the continued leasing momentum across our portfolio, reflecting our team's ongoing efforts to re-lease properties,” said Alan Gold, Executive Chairman of IIP. “At the same time, our recently announced $245 million mezzanine loan commitment at Alewife Park further expands our presence in the life science sector. Together, these initiatives reflect our focus on improving the performance of our existing portfolio while deploying capital into investments that we believe will drive earnings growth and create long-term value for our shareholders.”

Third Quarter 2026

Financial Results and Dividend

• Total revenues of $64.9 million and net income attributable to common stockholders of $28.7 million, or $0.99 per diluted share ( all per share amounts in this press release are reported on a diluted basis unless otherwise noted).

• Adjusted funds from operations ("AFFO") of $54.8 million, or $1.96 per share

• Declared dividends to common stockholders totaling $1.90 per share. Since its inception, IIP has paid over $1.2 billion in common stock dividends to its stockholders.

__________________________________________________________________

Amounts in thousands, except per share amounts. Definitions of the above-mentioned non-GAAP financial measures, together with reconciliations to net income in accordance with GAAP and other definitions of capitalized terms used herein, appear at the end of this release.

Life Science Investments

• In September, the Company entered into a $245.0 million mezzanine loan commitment to affiliates of IQHQ, Inc. in connection with Alewife Park, a life science campus located in Cambridge, Massachusetts, funding approximately $111.0 million at closing.

• The loan is expected to yield an interest rate of approximately 15.8% over the term of the loan, subject to a floor of 14.0%, and matures in February 2028, with a one-year extension option. The remaining $134.0 million is expected to be funded through the fourth quarter of 2027, subject to certain funding conditions.

• The Company also has the option to acquire up to an additional $155.0 million of mezzanine notes from another lender on the same terms, subject to certain conditions.

• In September, funded $30.0 million of IQHQ Series G preferred equity.

• As of September 30, 2026, the Company had funded an aggregate of $300.0 million of its strategic investment in IQHQ, Inc., consisting of a $100.0 million revolving credit facility and $200.0 million of Series G preferred equity.

Portfolio - Leasing and Dispositions

• During the three months ended September 30, 2026, the Company terminated 16 leases representing an aggregate of 1.2 million square feet, and entered into 6 leases representing 604,000 square feet.

• Subsequent to quarter end, the Company executed a new lease for its 270,000 square foot property in Saxton, Pennsylvania, contingent upon receipt of applicable cannabis license transfer approvals.¹

• In October, the Company received repayment in full of the $49.0 million seller financing provided in connection with the sale in May of its Perth, New York property.

Portfolio - Select Tenant Updates

• The following table summarizes payments received and security deposits applied for certain defaulted tenants during the periods presented and the corresponding per share impact (in millions, except per share amounts):

___________________________________________________________________

(1)

For the three months ended June 30, 2026, the weighted-average diluted shares outstanding for FFO, Normalized FFO and AFFO was 28,972,371 shares. For the three months ended September 30, 2026, the weighted-average diluted shares outstanding for FFO, Normalized FFO and AFFO was 27,961,629 shares.

• PharmaCann

• In August 2026, the Company entered into a new lease with Grown Rogue for the prior PharmaCann New York property. In September 2026, PharmaCann surrendered the Pennsylvania property and the two remaining Colorado properties. As of September 30, 2026, the Company has terminated all leases with PharmaCann.

• 4Front

• In August 2026, the Company terminated the lease with 4Front for its property located in Washington and entered into a new lease with a tenant for the property.

• As of September 30, 2026, the Company has three properties that remain leased to 4Front, representing 7.1% of the Company's annualized contractual rent as of September 30, 2026. The Company has reached tentative arrangements with prospective new tenants for the three assets leased to 4Front, including a 250,000 square foot asset in Illinois and two assets in Massachusetts totaling 124,000 square feet. Each of these arrangements is subject to certain contingencies to effectiveness (such as licensing transfer approvals) and are expected to go into effect at the conclusion of receivership proceedings, anticipated to occur by year end 2026 or early 2027.

• Parallel

• In July, Parallel defaulted under its two leases for properties located in Florida. In August, the Company regained possession of both of these properties.

• The Cannabist

• In September, the Company regained possession of seven properties leased to Cannabist. As of September 30, 2026, the Company leased 12 properties to Cannabist, representing 1.5% of our annualized contractual rent as of September 30, 2026.

• Battle Green

• ... (truncated)uted a guaranty of the lease.

Balance Sheet Highlights (at September 30, 2026)

• 18.7% net debt to total gross assets, with $3.0 billion in total gross assets.

• Total liquidity was $142.4 million, consisting of cash and cash equivalents.

• Net Debt to Adjusted EBITDA of 2.1x.

Financing Activity

• Preferred Stock

• Subsequent to quarter end, the Company completed an underwritten public offering of 2,167,500 shares of our 9.25% Series B Cumulative Redeemable Preferred Stock, which amount includes 167,500 shares² issued pursuant to the underwriters’ partial exercise of their overallotment option, at a public offering price of $25.00 per share, representing $54.2 million in gross proceeds.

• Credit Facility

• Subsequent to quarter end, the Company executed a 90-day extension of its $87.5 million revolving credit facility, extending the maturity date to January 21, 2027.

Financial Results

For the three months ended September 30, 2026, IIP generated total revenues of $64.9 million, compared to $64.7 million for the same period in 2025, an increase of 0.4%. The increase was driven by higher revenue related to properties repossessed during the third quarter of 2026 as a result of the application of security deposits, partially offset by lower rental revenue from property sales and lease terminations after the third quarter of 2025.

For the three months ended September 30, 2026, the Company applied $3.8 million of security deposits on properties leased to The Cannabist and Parallel. During the three months ended September 30, 2025, the Company applied $0.8 million of security deposits on two properties leased to Verdant and a Sacramento tenant.

For the three months ended September 30, 2026, interest and other income increased by $9.9 million to $14.3 million compared to $4.4 million for the three months ended September 30, 2025. The increase was primarily driven by the recognition of $10.4 million of interest and dividend income related to our financial investments in IQHQ, as well as interest income recognized on the seller-financed note associated with the sale of a property in Perth, New York.

Dividend

On September 15, 2026, the Board of Directors declared a third quarter 2026 dividend of $1.90 per common share, representing an annualized dividend of $7.60 per common share. The dividend was paid on October 15, 2026 to stockholders of record as of September 30, 2026.

Supplemental Information

Supplemental financial information is available in the Investor Relations section of IIP’s website at www.innovativeindustrialproperties.com.

Teleconference and Webcast

The Company will conduct a conference call and webcast at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) on Tuesday, November 3, 2026 to discuss IIP’s financial results and operations for the third quarter ended September 30, 2026. The call will be open to all interested investors through a live audio webcast at the Investor Relations section of IIP’s website at www.innovativeindustrialproperties.com, or live by calling 1-833-461-5787 (domestic) or 1-585-542-9983 (international) and asking to be joined to the Innovative Industrial Properties, Inc. conference call using meeting ID 339722854. The complete webcast will be archived for one year on IIP’s website. The website replay will be posted in the Investor Relations section of innovativeindustrialproperties.com.

About Innovative Industrial Properties

Innovative Industrial Properties, Inc. is a real estate investment trust (REIT) focused on the acquisition, ownership and management of specialized industrial properties and life science real estate. Additional information is available at www.innovativeindustrialproperties.com.

This press release contains statements that IIP believes to be “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts are forward-looking statements. When used in this press release, words such as IIP “expects,” “intends,” “plans,” “estimates,” “anticipates,” “believes” or “should” or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding potential transactions, including proposed leases of our properties, the consummation and timing of which remain subject to the negotiation and execution of definitive documentation, satisfaction of customary closing conditions and other contingencies, including those related to receivership sale processes; the anticipated timing, outcome and effects of pending receivership proceedings, including the effectiveness of arrangements with prospective new tenants for certain properties following the conclusion of such proceedings; and the expected transfer of existing cannabis licenses for certain properties to new tenants. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could materially affect actual results, performances or achievements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risk³... (truncated)es laws.⁴

#### Financial statements

##### Income Statement (For the Three Months Ended September 30, — (In thousands, except share and per share amounts))

| | For the Three Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenues** | | | | |
| Rental (including tenant reimbursements) | 64,743 | 64,292 | 196,553 | 198,855 |
| Other | 177 | 393 | 678 | 443 |
| Total revenues | 64,920 | 64,685 | 197,231 | 199,298 |
| **Expenses** | | | | |
| Property expenses | 6,939 | 7,951 | 21,711 | 22,197 |
| General and administrative expense | 8,458 | 8,681 | 26,526 | 25,768 |
| Depreciation and amortization expense | 19,572 | 18,639 | 56,955 | 55,530 |
| Impairment loss on real estate | 567 |  | 567 | 3,527 |
| Total expenses | 35,536 | 35,271 | 105,759 | 107,022 |
| Gain (loss) on sale of real estate, net |  |  | 12,269 |  |
| Income from operations | 29,384 | 29,414 | 103,741 | 92,276 |
| Interest and other income | 14,331 | 4,416 | 31,414 | 7,599 |
| Interest expense | -11,820 | -4,525 | -26,599 | -13,469 |
| Net income | 31,895 | 29,305 | 108,556 | 86,406 |
| Preferred stock dividends | -3,187 | -1,017 | -9,028 | -2,676 |
| Net income attributable to common stockholders | 28,708 | 28,288 | 99,528 | 83,730 |
| **Net income attributable to common stockholders per share** | | | | |
| Basic | 1.01 | 0.99 | 3.45 | 2.91 |
| Diluted | 0.99 | 0.97 | 3.38 | 2.87 |
| **Weighted-average shares outstanding** | | | | |
| Basic | 27,356,738 | 27,912,881 | 27,928,270 | 28,036,179 |
| Diluted | 27,961,629 | 28,303,600 | 28,465,209 | 28,402,063 |

##### Income Statement (For the Three Months Ended September 30, — (In thousands, except share and per share amounts))

| | For the Three Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income attributable to common stockholders | 28,708 | 28,288 | 99,528 | 83,730 |
| Real estate depreciation and amortization | 19,572 | 18,639 | 56,955 | 55,530 |
| Impairment loss on real estate | 567 |  | 567 | 3,527 |
| Loss (gain) on sale of real estate, net |  |  | -12,269 |  |
| FFO attributable to common stockholders | 48,847 | 46,927 | 144,781 | 142,787 |
| Litigation-related expense | 784 | 604 | 3,966 | 1,423 |
| Loss (gain) on partial repayment of notes due 2026 |  |  |  | -32 |
| Income on seller-financed notes(1) | 223 | -2,375 | 669 | -1,058 |
| Deferred lease payments received on sales-type leases(2) | 351 |  | 1,051 | 25 |
| Transaction costs and other(3) | 29 |  | -434 |  |
| Normalized FFO attributable to common stockholders | 50,234 | 45,156 | 150,033 | 143,145 |
| Stock-based compensation | 3,311 | 2,684 | 8,721 | 7,434 |
| Non-cash interest expense | 1,545 | 485 | 3,402 | 1,431 |
| Non-cash accretion of life science investments | -336 |  | -1,005 |  |
| Above-market lease amortization | 23 | 23 | 69 | 69 |
| AFFO attributable to common stockholders | 54,777 | 48,348 | 161,220 | 152,079 |
| FFO per common share – diluted | 1.75 | 1.66 | 5.09 | 5.03 |
| Normalized FFO per common share – diluted | 1.8 | 1.6 | 5.27 | 5.04 |
| AFFO per common share – diluted | 1.96 | 1.71 | 5.66 | 5.35 |
| **Weighted average common shares used for FFO, Normalized FFO, and AFFO:** | | | | |
| Basic | 27,356,738 | 27,912,881 | 27,928,270 | 28,036,179 |
| Restricted stock and RSUs | 604,891 | 390,719 | 536,939 | 365,884 |
| Diluted | 27,961,629 | 28,303,600 | 28,465,209 | 28,402,063 |

##### Income Statement (For the Three Months Ended September 30, 2026 — (In thousands))

| | For the Three Months Ended September 30, 2026 |
|---|---:|
| Net income | 31,895 |
| **Adjustments for EBITDA** | |
| Interest expense | 11,820 |
| Taxes (including corporate tax expense in G&A expense) | 1 |
| Depreciation and amortization expense | 19,572 |
| Above-market lease amortization | 23 |
| Non-cash accretion of life science investments | -336 |
| Corp. asset depreciation (included in G&A expense) | 23 |
| EBITDA | 62,998 |
| **Adjustments for Adjusted EBITDA** | |
| Stock-based compensation | 3,311 |
| Impairment loss on real estate | 567 |
| Income on seller-financed notes | 223 |
| Deferred lease payments received on sales-type leases | 351 |
| Transaction costs and other | 29 |
| Adjusted EBITDA | 67,479 |
| Adjusted EBITDA annualized | 269,916 |
| Total Debt | 711,561 |
| Cash and cash equivalents | -142,352 |
| Net Debt | 569,209 |
| Net Debt/Adjusted EBITDA | 2.1x |

##### Balance Sheet (September 30, — (In thousands, except share and per share amounts))

| | September 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| Land | 141,289 | 146,320 |
| Buildings and improvements | 2,191,688 | 2,269,597 |
| Construction in progress | 35,041 | 40,593 |
| Total real estate, at cost | 2,368,018 | 2,456,510 |
| Less accumulated depreciation | -387,234 | -343,062 |
| Net real estate held for investment | 1,980,784 | 2,113,448 |
| Life science investments | 417,416 | 152,665 |
| Loans receivable | 71,800 | 22,800 |
| Cash and cash equivalents | 142,352 | 47,597 |
| Restricted cash | 2,908 |  |
| In-place lease intangible assets, net | 3,727 | 6,366 |
| Other assets, net | 31,728 | 27,982 |
| Total assets | 2,650,715 | 2,370,858 |
| **Liabilities** | | |
| Notes due 2026, net |  | 290,602 |
| Exchangeable notes, net | 389,749 |  |
| Term loans, net | 118,710 |  |
